Study of Key Electro-acupuncture Technique on Migraine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200032
- Longhua Hospital,Shanghai University of Traditional Chinese Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- met the diagnostic criteria for migraine; suffering from migraine attacks; migraine attacks for more than 5 days per month, and lasts for 3 months; voluntarily join this study with informed consents.
Exclusion Criteria:
- other systemic, neurological and psychiatric disorders; headache caused by other diseases; not treatment compliance during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: electro-acupuncture
100hz, 2min.
electro-acupoint: LI4(Large Intestine4) with LV3(Liver3).5times
a week.
lasting for 4 weeks.
|
electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once
per day, for 20 days.
|
|
Active Comparator: routin medicine
one tablet of flunarizine hydrochloride tablet per day.
lasting for 20days
|
flunarizine hydrochloride ,10mg/day,for 20 days。
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Migraine Disability Assessment Questionnaire (MIDAS)
Time Frame: 20 days
|
a scientifically reliable and valid measure of migraine disability that can improve communication between patients and physicians, assess migraine severity and act as an outcome measure to monitor treatment efficacy
|
20 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The medical outcomes study 36-item short-form health survey(SF-36)
Time Frame: 20 days
|
A 36-item short-form (SF-36) was constructed to survey health status in the Medical Outcomes Study
|
20 days
|
|
peripheral Nitrogen Monoxide(NO) protein expression
Time Frame: 20 days
|
marker
|
20 days
|
|
peripheral Calcitonin gene related peptide(CGRP) protein expression
Time Frame: 20 days
|
marker
|
20 days
|
|
peripheral Nuclear factor-kappa B(NF-кB) protein expression
Time Frame: 20 days
|
marker
|
20 days
|
|
Visual Analogue Scale (VAS) to assess pain
Time Frame: 20 days
|
Visual Analogue Scale (VAS) were applied to measure pain in patients
|
20 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Jian Pei, Ph.D, Longhua Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Headache Disorders, Primary
- Headache Disorders
- Migraine Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Membrane Transport Modulators
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Flunarizine
Other Study ID Numbers
Other Study ID Numbers
- 643857003534
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
NCT06674772RecruitingMigraine | Migraine Headache | Migraine Without Aura | Migraine with Aura | Chronic Migraine, Headache | Episodic Migraine | Chronic Migraine Headache | Headache (Migraine) | Episodic Migraine Headache
-
NCT05281770RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic Migraine
-
NCT07599228Not yet recruitingMigraine Disorders | Migraine Without Aura | Migraine With Aura | Episodic Migraine
-
NCT04936061TerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic Migraine
-
NCT03177616CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, Classic
-
NCT05679908CompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura Migraine
-
NCT01804517CompletedChronic Migraine | Migraine Without Aura | Migraine With Aura
-
NCT02202486UnknownChronic Migraine | Migraine Without Aura | Migraine With Aura
-
NCT01596166CompletedMigraine Without Aura | Migraine With Aura | Probable Migraine
-
NCT00285402UnknownMigraine | Migraine Disorders | Migraine Headache | Migraine Without Aura | Migraine With Aura
Clinical Trials on electro-acupuncture
-
NCT04957134Completed
-
NCT01726504Completed
-
NCT01197950Completed
-
NCT05514067CompletedCoronary Artery Disease | Electro-Acupuncture
-
NCT01604356CompletedRetinitis Pigmentosa